147118-38-5

Usage

Uses

Used in Pharmaceutical Industry:
(3R,6E)-3-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-5-oxo-6-heptenoic acid methyl ester is used as a pharmaceutical agent for its potential to interact with various biological targets. Its unique molecular structure, including the silyl ether group, pyrimidinyl moiety, fluorophenyl group, and chiral center, may allow it to modulate enzyme activity, bind to receptors, or influence other biological processes, offering therapeutic benefits in treating specific diseases or conditions.
Used in Research Applications:
In the research field, (3R,6E)-3-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-5-oxo-6-heptenoic acid methyl ester serves as a valuable compound for studying its interactions with biological systems. Its complex structure and functional groups provide opportunities for investigating its binding affinity, selectivity, and mechanism of action, contributing to the understanding of molecular recognition and the development of novel therapeutic agents.

InChI:InChI=1/C29H42FN3O6SSi/c1-19(2)26-24(16-15-22(34)17-23(18-25(35)38-7)39-41(9,10)29(3,4)5)27(20-11-13-21(30)14-12-20)32-28(31-26)33(6)40(8,36)37/h11-16,19,23H,17-18H2,1-10H3/b16-15+/t23-/m1/s1

Upstream product

• 147118-37-4 N-[4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl]-N-methylmethanesulfonamide 
• 7152-15-0 ethyl 4-methyl-3-oxo-pentanoate 
• 122930-45-4 (E)-2-<(4-fluorophenyl)methylene>-4-methyl-3-oxopentanoic acid ethyl ester 
• 459-57-4 4-fluorobenzaldehyde 
• 147118-35-2 methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate 
• 147118-30-7 ethyl 2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-carboxylic acid 
• 147118-28-3 ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(methylsulfonyl)pyrimidine-5-carboxylate 
• 147118-36-3 N-[4-(4-fluorophenyl)-5-(hydroxymethyl)-6-(propan-2-yl)pyrimidin-2-yl]-N-methylmethanesulfonamide 
• 147118-27-2 ethyl 4-(4-fluorophenyl)-2-(methylsulfanyl)-6-(propan-2-yl)-pyrimidine-5-carboxylate 
• 147118-32-9 5-ethoxycarbonyl-6-(4'-fluorophenyl)-4-isopropyl-2-(methylamino)pyrimidine 

Downstream Products

• 147118-40-9 (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid methyl ester 
• 147118-39-6 methyl (3R,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3-hydroxy-5-oxohept-6-enoate 
• 1374771-96-6 rosuvastatin, S-benzylisothiourea salt 
• 852820-97-4 (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(isopropyl)pyrimidine-5-yl]-3,5-dihydroxyhept-6-enoic acid isopropylamine 
• 287714-41-4 rosuvastatin 

Relevant academic research and scientific papers

Preparation process of rosuvastatin calcium preparation

The invention provides a preparation process of a rosuvastatin calcium preparation, and belongs to the technical field of pharmaceutical preparations. With (3R)-tert-butyldimethylsiloxy-5-oxy-6-triphenylphosphoranylidene methyl caproate and 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonyl amino)pyridine-5-formaldehyde as initial raw materials, wittig reaction, deprotection reaction, chiral reduction reaction, hydrolysis reaction and purification are carried out so as to obtain a rosuvastatin calcium crude drug; then the rosuvastatin calcium crude drug is uniformly mixed with a diluent, a disintegrating agent, a stabilizing agent and a lubricant so as to obtain a mixture, and then the mixture is tabletted so as to obtain the rosuvastatin calcium preparation. The preparation process of the rosuvastatin calcium preparation disclosed by the invention has the advantages of simple operation, high yield, low cost and stable quality.

Preparing rosuvastatin calcium intermediates

The application provides a preparation method for a rosuvastatin calcium intermediate. The method comprises the following steps: a, condensation reaction: a step of adding a main chain Z8 and a side chain J6 into a mixed solution of toluene and acetonitrile, then adding 4-butylammonium bromide, carrying out heating and pressure-reduced concentration so as to obtain a crude H1 product; b, purification of a condensation product: a step of adding a mixture of n-hexane and petroleum ether, and carrying out heating, cooling, heating, filtering and pressure-reduced distillation so as to obtain a H1 product; c, deprotection reaction: a step of adding the H1 product into acetonitrile, then adding an acid-acetonitrile solution under ice bath, after completion of the reaction, controlling a pH value to 7 to 9, then separating the obtained solution and washing an organic layer, further separating the solution and adding a drying agent into the organic layer, then carrying out filtering and pressure-reduced concentration so as to obtain an oily substance, and adding tetrahydrofuran for crystallization so as to obtain an crude H2 product; and d, purification of a deprotection product: a step of adding acetone and tetrahydrofuran, after dissolving, adding activated carbon, and carrying out stirring, hot filtration, cooling, crystallization, filtering and vacuum drying so as to obtain a final H2 product. By using the preparation method for the rosuvastatin calcium intermediate provided by the invention, yield and purity are high, and cost is low.

A rosuvastatin calcium impurity preparation method

The invention discloses a preparation method of a rosuvastatin calcium impurity. The target compound is produced from 4-(4-fluorophenyl)-6-isopropyl-2(N-methyl-methanesulfonylamino)pyrimidine-5-yl]-formaldehyde and methyl (3R)-3-t-butyldimethylsiloxy-5-carbonyl-6-(triphenylphosphinevinyl)caproate through a Witting reaction, HF deprotection, alkaline hydrolysis and an acidifying reaction. The method has the characteristics of short synthesis route, simple operation, convenient post-treatment, and high purity and high yield of the product. The method provides certain help for register reporting of rosuvastatin calcium, production middle control and improvement of the quality of rosuvastatin calcium.

Integrated Biocatalysis in Multistep Drug Synthesis without Intermediate Isolation: A de Novo Approach toward a Rosuvastatin Key Building Block

In this contribution, we report the chemoenzymatic preparation of a key building block for the active pharmaceutical ingredient rosuvastatin, one of the "top 5 blockbuster drugs" with a worldwide market value of 6.25 billion USD in 2012, via a seven-step synthesis without isolation of intermediates and with incorporation of two highly efficient biotransformations. This chemoenzymatic process reaches excellent space-time yields by using high substrate concentrations (several hundred grams per liter), emphasizing the potential of biocatalysis for industrial processes related to pharmaceutical drug synthesis and the compatibility of enzyme chemistry with classical organic synthesis.

PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM VIA NOVEL AMINE INTERMEDIATE

The present invention, relates to novel amine salts of rosuvastatin and its process for the preparation. Moreover, the present invention also relates to improved process for the preparation of rosuvastatin calcium, employing novel amine salts as an intermediate.

PREPARATION METHOD OF ROSUVASTATIN CALCIUM AND ITS INTERMEDIATES

.A preparation method of rosuvastatin calcium (Formula 1), which can be used for the production of medicament lowering the levels of LDL-cholesterol and triglycerides in vivo, is provided. Such preparation method is suitable for industrial production. Furthermore, the intermediate crystallines used in the preparation method are provided.

A METHOD FOR THE PURIFICATION OF ROSUVASTATIN INTERMEDIATE

The present invention relates to a method for the purification of an intermediate of formula (1), which is useful for the preparation of Rosuvastatin and its pharmaceutically acceptable salts thereof, more particularly purification method comprises the addition of aqueous organic acid such as acetic acid under stirring conditions in presence of an organic solvent such as isopropyl ether or alternatively the purification method comprises the addition of aqueous alcohol such as methanol under stirring conditions in presence of an organic solvent such as isopropyl ether (Formula I)

ROSUVASTATIN DEHYDROABIETYLAMINE SALT

There is provided a compound, which is dehydroabietylamine salt of rosuvastatin. Also provided are processes for making rosuvastatin calcium that include formation of dehydroabietylamine salt of rosuvastatin.

A PROCESS FOR THE PREPARATION OF ROSUVASTATIN INVOLVING A TEMPO-MEDIATED OXIDATION STEP

The present invention provides a process for the preparation of the rosuvastatin intermediate FPP-CHO and its conversion to rosuvastatin and pharmaceutically acceptable salts thereof.

PREPARATION OF ROSUVASTATIN

Provided are processes for preparing intermediates of rosuvastatin and their use in preparation of rosuvastatin and rosuvastatin salts thereof.